Prognostic significance of β-catenin, E-cadherin, and SOX9 in colorectal cancer: Results from a large population-representative series

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Bruun, Jarle ^a,b   Kolberg, Matthias ^a,b   Nesland, Jahn M ^b,c   Svindland, Aud ^b,c   Nesbakken, Arild ^b,d   Lothe, Ragnhild A ^a,b,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Beta catenin; Biomarker discovery; Colorectal cancer; E cadherin; Guideline adherence; Prognostic biomarkers; SOX9 transcription factor

Indexed keywords

BETA CATENIN; TRANSCRIPTION FACTOR SOX9; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CYTOSOL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PROTEIN DEPLETION; PROTEIN EXPRESSION; TISSUE MICROARRAY; VERY ELDERLY;

EID: 84904619083     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00118     Document Type: Article

References (73)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127:2893-917. doi: 10.1002/ijc.25516
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008-2030): a population-based study. Lancet Oncol (2012) 13(8):790-801. doi:10.1016/S1470-2045(12)70211-5
3. Merok MA, Ahlquist T, Royrvik EC, Tufteland KF, Hektoen M, Sjo OH, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol (2012) 24(5):1274-82. doi:10.1093/annonc/mds614
4. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 345(15):1091-7. doi:10.1056/NEJMoa010957
5. Abraham A, Habermann EB, Rothenberger DA, Kwaan M, Weinberg AD, Parsons HM, et al. Adjuvant chemotherapy for stage III colon cancer in the oldest old: results beyond clinical guidelines. Cancer (2013) 119(2):395-403. doi:10.1002/cncr.27755
6. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al. Identification of FAP locus genes from chromosome 5q21. Science (1991) 253(5020):661-5. doi:10.1126/science.1651562
7. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science (1991) 253(5020):665-9. doi:10.1126/science.1651563
8. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, et al. Association of the APC gene product with beta-catenin. Science (1993) 262:1731-4. doi:10.1126/science.8259518
9. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science (1993) 262(5140):1734-7. doi:10.1126/science.8259519
10. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell (1990) 61:759-67. doi:10.1016/0092-8674(90)90186-I
11. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell (1996) 87:159-70. doi:10.1016/S0092-8674(00)81333-1
12. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 275(5307):1787-90. doi:10.1126/science.275.5307.1787
13. Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO, et al. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia (2005) 7:99-108. doi:10.1593/neo.04448
14. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science (2007) 318(5853):1108-13. doi:10.1126/science.1145720
15. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 487:330-7. doi:10.1038/nature11252
16. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell (2012) 149(6):1192-205. doi:10.1016/j.cell.2012.05.012
17. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer (2002) 34(3):255-68. doi:10.1002/gcc.10083
18. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res (2008) 28:3815-26.
19. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 9(7):489-99. doi:10.1038/nrc2645
20. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol (2011) 6:479-507. doi:10.1146/annurev-pathol-011110-130235
21. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut (2005) 54(9):1283-6. doi:10.1136/gut.2005.066514
22. Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano L, et al. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology (2007) 50:453-64. doi:10.1111/j.1365-2559.2007.02620.x
23. Lovig T, Meling GI, Diep CB, Thorstensen L, Norheim AS, Lothe RA, et al. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status. Scand J Gastroenterol (2002) 37(10):1184-93. doi:10.1080/003655202760373407
24. Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res (2012) 72:1301-15. doi:10.1158/0008-5472.CAN-11-3660
25. Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis (2000) 21(11):1935-40. doi:10.1093/carcin/21.11.1935
26. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res (2001) 7(12):4013-20.
27. Elzagheid A, Buhmeida A, Korkeila E, Collan Y, Syrjanen K, Pyrhonen S. Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma. World J Gastroenterol (2008) 14:3866-71. doi:10.3748/wjg.14.3866
28. Wanitsuwan W, Kanngurn S, Boonpipattanapong T, Sangthong R, Sangkhathat S. Overall expression of beta-catenin outperforms its nuclear accumulation in predicting outcomes of colorectal cancers. World J Gastroenterol (2008) 14(39):6052-9. doi:10.3748/wjg.14.6052
29. Norwood MG, Bailey N, Nanji M, Gillies RS, Nicholson A, Ubhi S, et al. Cytoplasmic beta-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas. Histopathology (2010) 57(1):101-11. doi:10.1111/j.1365-2559.2010.03587.x
30. Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer. Diagn Pathol (2013) 8:10-8. doi:10.1186/1746-1596-8-10
31. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 305(16):1685-94. doi:10.1001/jama.2011.513
32. Bondi J, Bukholm G, Nesland JM, Bukholm IR. Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS (2004) 112:49-56. doi:10.1111/j.1600-0463.2004.apm1120109.x
33. Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F. A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer (2002) 95:2479-86. doi:10.1002/cncr.10986
34. Martensson A, Oberg A, Jung A, Cederquist K, Stenling R, Palmqvist R. Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep (2007) 17(2):447-52.
35. Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, et al. Prognostic significance of Wnt-1, beta-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res (2011) 17(4):955-63. doi:10.1007/s12253-011-9409-4
36. Andras C, Toth L, Molnar C, Tanyi M, Csiki Z, Dezso B, et al. Correlations between clinicopathological parameters and molecular signatures of primary tumors for patients with stage T3n0 colorectal adenocarcinomas: a single center retrospective study on 100 cases. Hepatogastroenterology (2012) 59(116):1091-7. doi:10.5754/hge12041
37. Elzagheid A, Buhmeida A, Laato M, El-Faitori O, Syrjanen K, Collan Y, et al. Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma. APMIS (2012) 120(7):539-48. doi:10.1111/j.1600-0463.2011.02863.x
38. Matsuoka T, Mitomi H, Fukui N, Kanazawa H, Saito T, Hayashi T, et al. Cluster analysis of claudin-1 and -4, E-cadherin, and beta-catenin expression in colorectal cancers. J Surg Oncol (2011) 103(7):674-86. doi:10.1002/jso.21854
39. Blache P, van de WM, Duluc I, Domon C, Berta P, Freund JN, et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol (2004) 166:37-47. doi:10.1083/jcb.200311021
40. Yano F, Kugimiya F, Ohba S, Ikeda T, Chikuda H, Ogasawara T, et al. The canonical Wnt signaling pathway promotes chondrocyte differentiation in a Sox9-dependent manner. Biochem Biophys Res Commun (2005) 333(4):1300-8. doi:10.1016/j.bbrc.2005.06.041
41. Akiyama H, Lyons JP, Mori-Akiyama Y, Yang X, Zhang R, Zhang Z, et al. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev (2004) 18(9):1072-87. doi:10.1101/gad.1171104
42. Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting beta-catenin phosphorylation in the nucleus. J Biol Chem (2009) 284(5):3323-33. doi:10.1074/jbc.M808048200
43. Lu B, Fang Y, Xu J, Wang L, Xu F, Xu E, et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol (2008) 130:897-904. doi:10.1309/AJCPW1W8GJBQGCNI
44. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med (2012) 9(5):e1001216. doi:10.1371/journal.pmed.1001216
45. Sjo OH, Merok MA, Svindland A, Nesbakken A. Prognostic impact of lymph node harvest and lymph node ratio in patients with colon cancer. Dis Colon Rectum (2012) 55(3):307-15. doi:10.1097/DCR.0b013e3182423f62
46. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 4:844-7. doi:10.1038/nm0798-844
47. Skotheim RI, Abeler VM, Nesland JM, Fossa SD, Holm R, Wagner U, et al. Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. Neoplasia (2003) 5:397-404. doi:10.1016/S1476-5586(03)80042-8
48. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11:155-68.
49. Hallgren KA. Computing inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol (2012) 8(1):23-34.
50. Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst (2007) 99:998-1003. doi:10.1093/jnci/djm024
51. Birchmeier W, Weidner KM, Hulsken J, Behrens J. Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas. Semin Cancer Biol (1993) 4(4):231-9.
52. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol (1993) 5(5):806-11. doi:10.1016/0955-0674(93)90029-P
53. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta (1994) 1198:11-26.
54. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene (2008) 27(55):6920-9. doi:10.1038/onc.2008.343
55. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev (2009) 28:151-66. doi:10.1007/s10555-008-9179-y
56. Hao X, Tomlinson I, Ilyas M, Palazzo JP, Talbot IC. Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours. Virchows Arch (1997) 431:167-72. doi:10.1007/s004280050084
57. Kobayashi M, Honma T, Matsuda Y, Suzuki Y, Narisawa R, Ajioka Y, et al. Nuclear translocation of beta-catenin in colorectal cancer. Br J Cancer (2000) 82:1689-93.
58. Filiz AI, Senol Z, Sucullu I, Kurt Y, Demirbas S, Levhi AM. The survival effect of E-cadherin and catenins in colorectal carcinomas. Colorectal Dis (2009) 12(12):1223-30.
59. Chen Z, He X, Jia M, Liu Y, Qu D, Wu D, et al. Beta-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis. PLoS One (2013) 8(5):e63854. doi:10.1371/journal.pone.0063854
60. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics (2000) 56(2):455-63. doi:10.1111/j.0006-341X.2000.00455.x
61. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 98:10356-61. doi:10.1073/pnas.171610498
62. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology (2002) 122(1):60-71. doi:10.1053/gast.2002.30306
63. Bandapalli OR, Dihlmann S, Helwa R, Her-Goeppinger S, Weitz J, Schirmacher P, et al. Transcriptional activation of the beta-catenin gene at the invasion front of colorectal liver metastases. J Pathol (2009) 218:370-9. doi:10.1002/path.2539
64. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia (2007) 9(7):569-77. doi:10.1593/neo.07760
65. Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch (2007) 451(4):763-9. doi:10.1007/s00428-007-0466-8
66. Albuquerque C, Bakker ER, van VW, Smits R. Colorectal cancers choosing sides. Biochim Biophys Acta (2011) 1816(2):219-31. doi:10.1016/j.bbcan.2011.07.005
67. Albuquerque C, Baltazar C, Filipe B, Penha F, Pereira T, Smits R, et al. Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer (2010) 49(8):746-59. doi:10.1002/gcc.20786
68. Leedham SJ, Rodenas-Cuadrado P, Howarth K, Lewis A, Mallappa S, Segditsas S, et al. A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts. Gut (2013) 62(1):83-93. doi:10.1136/gutjnl-2011-301601
69. Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F, et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis. Oncogene (2013) 32(39):4675-82. doi:10.1038/onc.2012.486
70. Bakker ER, Hoekstra E, Franken PF, Helvensteijn W, van Deurzen CH, van VW, et al. Beta-catenin signaling dosage dictates tissue-specific tumor predisposition in Apc-driven cancer. Oncogene (2013) 32(38):4579-85. doi:10.1038/onc.2012.449
71. Goentoro L, Kirschner MW. Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell (2009) 36(5):872-84. doi:10.1016/j.molcel.2009.11.017
72. Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, et al. Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer (2012) 131(7):1649-58. doi:10.1002/ijc.26192
73. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 134(11):2513-22. doi:10.1002/ijc.28384